FibroBiologics ends sublease, saves $0.8M rent
FibroBiologics, Inc. terminated its sublease for office space in Webster, Texas through a Sublease Buyout Agreement effective April 2, 2026, well before the original November 30, 2027 end date.
Rhea-AI Filing Summary
FibroBiologics, Inc. terminated its sublease for office space in Webster, Texas through a Sublease Buyout Agreement effective April 2, 2026, well before the original November 30, 2027 end date. The company made a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent.
The change follows FibroBiologics’ 2025 opening of a new state-of-the-art laboratory facility with over 10,000 square feet of lab and office space and supports its consolidation of operations. The company’s principal executive offices are now located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Lease termination payment: $45,108.25
Expected rent savings: approximately $0.8 million
Lab facility size: over 10,000 square feet
+3 more
6 metrics
Lease termination payment
$45,108.25
Single payment to resolve remaining rent obligations under sublease
Expected rent savings
approximately $0.8 million
Future rent savings from early sublease termination
Lab facility size
over 10,000 square feet
State-of-the-art laboratory and office space opened in 2025
Sublease termination date
April 2, 2026
Effective date of Lease Termination Agreement
Original sublease expiration
November 30, 2027
Initial end date of sublease before buyout
New principal office address
9350 Kirby Drive, Suite 300, Houston, TX 77054
Updated location of principal executive offices
Key Terms
Sublease Buyout Agreement, Lease Termination Agreement, Sublease Agreement, principal executive offices, +1 more
5 terms
Sublease Buyout Agreement financial
"entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”)"
Lease Termination Agreement financial
"entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”)"
Sublease Agreement financial
"terminate that certain Sublease Agreement, which was effective as of October 5, 2022"
principal executive offices regulatory
"The new address of the Company’s principal executive offices is 9350 Kirby Drive"
emerging growth company regulatory
"Emerging growth company Item 1.01 Entry into a Material Definitive Agreement."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What lease change did FibroBiologics (FBLG) disclose in this 8-K?
FibroBiologics terminated its sublease for space at 455 E. Medical Center Blvd in Webster, Texas. The Sublease Buyout Agreement ended the sublease effective April 2, 2026, which was well ahead of its original November 30, 2027 expiration date.
How much will FibroBiologics (FBLG) pay and save from the sublease termination?
FibroBiologics resolved its remaining rent obligations with a single payment of $45,108.25. By ending the sublease early, the company expects to save approximately $0.8 million in future rent payments, reducing ongoing office-related costs and supporting its operational consolidation.
Why is FibroBiologics consolidating office space according to the filing?
The company is consolidating after opening a state-of-the-art laboratory facility in 2025 with over 10,000 square feet of lab and office space. Ending the older sublease eliminates redundant office costs and allows more resources to be directed toward advancing fibroblast-based therapeutics.
What is the new principal executive office address for FibroBiologics (FBLG)?
FibroBiologics’ principal executive offices are now located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054. This new address reflects the company’s post-consolidation headquarters location following the termination of its prior sublease in Webster, Texas.
How far ahead of schedule did FibroBiologics end its sublease?
The company ended its sublease effective April 2, 2026, compared with the original November 30, 2027 expiration date. This means the sublease was concluded roughly 18 months ahead of schedule, contributing to the expected rent savings noted in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
